ASTH vs CLOV vs HUM vs ALHC

For growth investors, Astrana Health, Inc.

(ASTH) is the stronger pick with 56. 4% revenue growth year-over-year, versus 10. 1% for Humana Inc. (HUM). Humana Inc. (HUM) offers the better valuation at 25. 1x trailing P/E (27. 7x forward), making it the more compelling value choice. Analysts rate Astrana Health, Inc. (ASTH) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Humana Inc.

(HUM) is the cheapest at 25. 1x versus Astrana Health, Inc. at 78. 4x. On forward P/E, Humana Inc. is actually cheaper at 27. 7x.

Over the past 5 years, Astrana Health, Inc.

(ASTH) delivered a total return of +7. 8%, compared to -67. 3% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: ASTH returned +614. 5% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Humana Inc.

(HUM) is the lower-risk stock at 0. 56β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately 117% more volatile than HUM relative to the S&P 500. On balance sheet safety, Humana Inc. (HUM) carries a lower debt/equity ratio of 73% versus 193% for Astrana Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Astrana Health, Inc.

(ASTH) is pulling ahead at 56. 4% versus 10. 1% for Humana Inc. (HUM). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, ASTH leads at 40. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Humana Inc.

(HUM) is the more profitable company, earning 0. 9% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ASTH leads at 2. 5% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — CLOV leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Humana Inc.

(HUM) trades at 27. 7x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 113. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.

In this comparison, HUM (1.

4% yield), ASTH (0. 4% yield) pay a dividend. CLOV, ALHC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Humana Inc.

(HUM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), 1. 4% yield). Both have compounded well over 10 years (HUM: +59. 8%, CLOV: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ASTH is a small-cap high-growth stock; CLOV is a small-cap high-growth stock; HUM is a mid-cap quality compounder stock; ALHC is a small-cap high-growth stock. HUM pays a dividend while ASTH, CLOV, ALHC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.